2026-08-19T16:30:57-05:00 2025-12-31 800682248 CHARLES M MOCHE CPA 2050 CENTER AVENUE SUITE 435 FORT LEE NJ 07024 990 2025-01-01 562427805 AIM AT MELANOMA AIMA 9167060599 3053 FREEPORT BLVD SUITE 222 SACRAMENTO CA 95818 SAMANTHA GUILD PRESIDENT 9167060599 2026-08-19 1 CHARLES M MOCHE P00641894 2014651800 2026-08-10 X 2025 2025-03-06 01:10:19Z SAMANTHA GUILD 3053 FREEPORT BLVD SUITE 222 SACRAMENTO CA 95818 2845964 0 X WWW.AIMATMELANOMA.ORG X 2004 CA TO SUPPORT MELANOMA RESEARCH; TO PROMOTE PREVENTION AND EDUCATION AMONG THE GENERAL PUBLIC AND MEDICAL PROFESSIONALS; AND TO PROVIDE COMPREHENSIVE AND EASILY ACCESSIBLE MELANOMA RESOURCES FOR PATIENTS, SURVIVORS, AND CAREGIVERS. 5 4 9 0 0 0 2750295 2588899 8315 12904 212479 229528 0 -159870 2971089 2671461 475000 295000 0 0 893172 926725 0 0 115382 961179 835999 2329351 2057724 641738 613737 6666866 7268877 19708 7982 6647158 7260895 X AIM AT MELANOMA (AIM) IS GLOBALLY ENGAGED AND LOCALLY INVESTED IN ADVANCING THE BATTLE AGAINST MELANOMA THROUGH INNOVATIVE RESEARCH, LEGISLATIVE REFORM, EDUCATION, AND PATIENT AND CAREGIVER SUPPORT. FOUNDED IN 2004, AIM AT MELANOMA IS THE LARGEST INTERNATIONAL MELANOMA FOUNDATION SEEKING THE CURE FOR MELANOMA. AIM BELIEVES THAT THE CURE FOR MELANOMA WILL BE FOUND MORE QUICKLY BY BRINGING TOGETHER LEADING GLOBAL RESEARCHERS AND FUNDING THEIR COLLABORATIVE RESEARCH. OUR THREE PARADIGM-SHIFTING GLOBAL RESEARCH INITIATIVES, INCLUDING THE MELANOMA TISSUE BANK CONSORTIUM, ARE POISED TO RESHAPE THE FUTURE OF MELANOMA. AIM IS THE RESPECTED VOICE OF MELANOMA ACROSS THE NATION. WHEN DRUGS ARE APPROVED, LEGISLATION IS DRAFTED, AND RESEARCH IS ASSESSED, AIM IS AT THE TABLE, SPEAKING LOUDLY AND CLEARLY ON BEHALF OF PATIENTS AND THEIR FAMILIES. AIM IS THE TRUSTED ADVISOR FOR PHARMACEUTICAL COMPANIES, MEDICAL BOARDS, AND GOVERNMENT AGENCIES ON CRITICAL TOPICS THAT AFFECT MELANOMA PATIENTS. 0 0 1838518 295000 10100 WEBSITEAIM AT MELANOMA ("AIM") IS THE LARGEST INTERNATIONAL ORGANIZATION ENGAGED IN A WIDE RANGE OF GLOBAL PATIENT ADVOCACY INITIATIVES FOR THE PURPOSE OF RAISING AWARENESS ABOUT MELANOMA AND SUPPORTING THOSE IMPACTED BY THE DISEASE BY PROVIDING COMPREHENSIVE EDUCATION, ADVOCATING FOR PATIENTS AND THEIR FAMILIES, AND FUNDING COLLABORATIVE RESEARCH INITIATIVES. AMONG OUR MOST IMPORTANT CONTRIBUTIONS TO THE MELANOMA COMMUNITY IS THE OWNERSHIP AND MAINTENANCE OF THE MOST COMPREHENSIVE U.S. WEBSITE ON MELANOMA (WWW.AIMATMELANOMA.ORG). IN 2025, AIM CONTINUED TO CREATE WEBSITE CONTENT FOR THE PURPOSE OF MEETING THE NEEDS OF THE MELANOMA COMMUNITY. THIS INCLUDED, BUT WAS NOT LIMITED TO, MAKING IT EASIER FOR USERS TO IDENTIFY PERTINENT INFORMATION TO ASSIST THEM IN BETTER UNDERSTANDING THEIR MELANOMA DIAGNOSIS AND STAGING, TREATMENT OPTIONS, CLINICAL TRIAL OPPORTUNITIES, RECOGNITION AND MANAGEMENT OF THE SIDE EFFECTS OF TREATMENT, RISK OF RECURRENCE, FOLLOW-UP CARE, AND THE PSYCHOSOCIAL ASPECTS OF THE DISEASE. THE ORGANIZATION CONTINUED TO USE VARIOUS METHODS, SUCH AS SEARCH ENGINE OPTIMIZATION, SOCIAL MEDIA, AND BROCHURES DISTRIBUTED TO HEALTHCARE PROVIDERS THROUGHOUT THE U.S, AND OTHER REGIONS OF THE WORLD AND TO BROADEN OUR REACH AND TO EDUCATE PATIENTS AND THEIR FAMILIES ABOUT THE WEBSITE'S RESOURCES. THE WEBSITE WAS UPDATED REGULARLY FOR MEDICAL ACCURACY IN ORDER TO REFLECT THE CURRENT STANDARD OF CARE IN MELANOMA AND WITH CONTENT RELATED TO ISSUES FACING THE MELANOMA COMMUNITY. AS PART OF AIM'S COMMITMENT TO EQUITY IN MELANOMA EDUCATION, AIM INVESTED IN GLOBAL ACCESSIBILITY, MAKING SURE LANGUAGE WAS NOT A BARRIER TO LIFESAVING INFORMATION. AMONG OTHER THINGS, AIM'S WEBSITE WAS CONFIGURED FOR MULTIPLE LANGUAGES, PROVIDING FULL-SITE TRANSLATION SO THAT THE INFORMATION COULD REACH A BROADER AUDIENCE. AIM ALSO STARTED THE PROCESS OF TRANSLATING MANY EDUCATIONAL MATERIALS INTO SPANISH. AIM'S WEBSITE ALONE HAD AROUND 100,000 UNIQUE VISITORS EACH MONTH. THIS IS AN INCREASE FROM 2024. APPROXIMATELY HALF OF THE WEBSITE'S TRAFFIC CAME FROM OUTSIDE OF THE U.S.PATIENT ADVOCACYTHROUGHOUT 2025, AIM CONTINUED TO PROVIDE A FREE ONCOLOGY PHYSICIAN ASSISTANT ON CALL SERVICE THROUGH ITS ASK AN EXPERT INITIATIVE. PATIENTS WITH MELANOMA, CAREGIVERS, AND FAMILIES REACHED OUT TO ASK QUESTIONS ABOUT, AMONG OTHER THINGS, THEIR/THEIR LOVED ONE'S MELANOMA DIAGNOSIS, TREATMENT OPTIONS, CLINICAL TRIALS, SIDE EFFECT MANAGEMENT, AND FOLLOW-UP CARE AS WELL AS QUESTIONS REGARDING PREVENTION AND EARLY DETECTION OF THE DISEASE. AIM CONTINUED TO COORDINATE NUMEROUS PATIENT ADVOCACY EVENTS, WHICH INCLUDED 10 PATIENT AND CAREGIVER SYMPOSIA LED BY NATIONALLY RECOGNIZED ONCOLOGISTS WHO SPECIALIZE IN MELANOMA AT MAJOR CANCER CENTERS SUCH AS SIDNEY COMPREHENSIVE CANCER AT JOHNS HOPKINS, MICHIGAN ROGEL COMPREHENSIVE CANCER CENTER, CARBONE CANCER CENTER AT UW-MADISON AND UPMC HILLMAN CANCER CENTER. THE SYMPOSIA ARE OFFERED AS HYBRID EVENTS SO THAT INDIVIDUALS CAN ATTEND IN-PERSON BUT CAN ALSO WATCH VIA LIVE STREAM. AIM ALSO VIDEOTAPED AND EDITED THESE SYMPOSIA, WHICH WERE THEN UPLOADED ONTO YOUTUBE AND AIM'S WEBSITE SO THEY COULD BE VIEWED BY INDIVIDUALS IN THE U.S. AND WORLDWIDE AT ANY TIME. AIM CONTINUED TO PROVIDE SUPPORT FOR PATIENTS, FAMILIES, AND SURVIVORS THROUGH A PROGRAM CALLED PEER CONNECT. PEER CONNECT IS A PEER-TO-PEER SUPPORT PROGRAM, AIM AT MELANOMA'S ANSWER TO THE ONGOING NEED FOR SUPPORT IN THE MELANOMA COMMUNITY. PATIENTS WITH MELANOMA, FAMILY MEMBERS, AND CAREGIVERS WHO JOIN THE PROGRAM ARE MATCHED WITH A PEER, AND FROM THERE THE PAIR COMMUNICATE IN A WAY THAT IS COMFORTABLE FOR BOTH. MEMBERS OF PEER CONNECT PROVIDE EACH OTHER WITH KNOWLEDGE, EXPERIENCE, EMOTIONAL SUPPORT, AND MORE. IN RESPONSE TO A FIRST-EVER FDA-APPROVED TREATMENT OPTION USING TIL THERAPY, AIM DEVELOPED A PEER-TO-PEER PROGRAM SPECIFIC TO THIS PATIENT POPULATION BY MATCHING "MENTORS" TO THOSE UNDERGOING THE THERAPY TO GUIDE OTHERS IN SELF-ADVOCACY, AND PROVIDE MEANINGFUL EMOTIONAL SUPPORT TO THOSE UNDERGOING THE SAME TREATMENT. IN 2025, AIM CONTINUED TO INCREASE THE NUMBER OF INDIVIDUALS WHO PARTICIPATED IN THE PEER CONNECT PROGRAM. AIM CONTINUES TO MAINTAIN A VERY ACTIVE FACEBOOK PAGE, AN X ACCOUNT (FORMERLY KNOWN AS TWITTER), AN INSTAGRAM ACCOUNT, AND A YOUTUBE CHANNEL IN ORDER TO PROVIDE OTHER SOURCES OF INFORMATION FOR THE MELANOMA COMMUNITY.AIM CONTINUED TO REPRESENT PATIENTS ON THE TWO LARGEST U.S. COOPERATIVE ONCOLOGY GROUPS, SWOG AND ECOG-ACRIN, THE NCCN, THE ASCO GUIDELINES COMMITTEE, AND THE AAD GUIDELINES OF CARE FOR THE MANAGEMENT OF CUTANEOUS MELANOMA COMMITTEE. AIM ALSO PRESENTED ON THE MELANOMA PATIENT PERSPECTIVE AT NUMEROUS MEETINGS BOTH IN THE U.S. AND THROUGHOUT THE WORLD. AIM SPOKE ON THE IMPORTANCE OF ENSURING THAT PATIENTS' NEEDS, EXPERIENCES AND PREFERENCES WERE INCORPORATED IN ALL HEALTHCARE DECISION-MAKING, FROM SHAPING RESEARCH PRIORITIES TO CO-CREATING CARE PLANS.TO HELP PATIENTS UNDERSTAND THEIR DISEASE, AIM CONTINUED TO OFFER FROM THE CLINIC TO THE LIVING ROOM, A WEBINAR SERIES THAT IS LIVE STREAMED THROUGH FACEBOOK AND PROVIDES AN IN-DEPTH DISCUSSION ON A SPECIFIC TOPIC WITH A MELANOMA SPECIALIST, SUCH AS AN ONCOLOGIST, RESEARCHER, OR OTHER MEDICAL EXPERT WHO SPECIALIZES IN MELANOMA. AIM ALSO CONTINUED TO OFFER BEYOND THE CLINIC: LIVING WELL WITH MELANOMA, A PODCAST SERIES TO ADDRESS THE PSYCHOSOCIAL ASPECTS OF A MELANOMA DIAGNOSIS DURING AND BEYOND TREATMENT. AIM ALSO CONTINUED TO OFFER MELANOMA360 BLOG, WHICH FEATURES SURVIVOR STORIES, RESEARCH BREAKTHROUGHS, CURRENT NEWS, HEALTH LIVING INFORMATION ETC.AIM ESTABLISHED ITS ROLE AS THE PATIENT ADVOCACY LEADER IN MELANOMA STANDING UP FOR PATIENTS WITH MELANOMA. WHEN A TREATMENT OPTION WAS DENIED BY THE FDA, HUNDREDS OF PATIENTS AND THEIR LOVED ONES REACHED OUT TO AIM STATING THEY WERE DEVASTATED BY THE DENIAL OF A PROMISING TREATMENT OPTION FOR PATIENTS WHOSE MELANOMA DOES NOT RESPOND TO IMMUNOTHERAPY. IT WAS AIM THAT LED THE EFFORT TO WRITE A LETTER URGING THE FDA TO RECONSIDER ITS DECISION. NATIONAL MELANOMA ORGANIZATIONS JOINED AIM AS SIGNATORIES. AIM ALSO MET WITH THE OFFICES OF POLICYMAKERS AND PUBLISHED A LETTER IN THE WALL STREET JOURNAL, FOCUSING ON THE NEED TO MAINTAIN TRUST IN THE CLINICAL TRIALS SYSTEM AND HOW THE DENIAL THREATENED THAT TRUST. GLOBAL ADVOCACYAIM'S PATIENT ADVOCACY IS A GLOBAL EFFORT. IN 2025, AIM CONTINUED TO SUPPORT AND MENTOR PATIENT ADVOCACY GROUPS IN THE UNITED KINGDOM, PORTUGAL, GERMANY, FRANCE, ITALY, SPAIN, ISRAEL, LATIN AMERICA, BRAZIL, CANADA, AUSTRALIA, EASTERN EUROPE, AND NIGERIA. AIM MADE IT POSSIBLE FOR THE PATIENT ADVOCATES TO ATTEND INTERNATIONAL MELANOMA MEETINGS, EITHER IN PERSON OR VIRTUALLY, WHERE THEY LEARNED THE MOST UP TO DATA INFORMATION ON MELANOMA, AND WHERE THEY PRESENTED THE PATIENT PERSPECTIVE TO RELEVANT GROUPS. AIM CONTINUED TO ASSIST IN THE DEVELOPMENT OF SOME OF THEIR RESPECTIVE WEBSITES PROVIDING NOT ONLY TECHNICAL SUPPORT BUT ALSO MATERIAL FOR THEIR SITES. AIM HELD ITS YEARLY IN-PERSON MEETING IN GERMANY FOR GLOBAL PATIENT ADVOCATES IN ORDER TO HELP THEM LEARN MORE ABOUT MELANOMA ADVANCEMENTS. AIM ALSO VIRTUALLY MET WITH GLOBAL ADVOCATES TO HELP PROMOTE COLLABORATIONS ON YEAR-LONG PROJECTS, TO PROVIDE EACH OTHER FEEDBACK ON INDIVIDUAL REGIONAL PROJECTS, TO SHARE BEST PRACTICES, AND TO LEARN ABOUT RESULTS OF CLINICAL TRIALS. AS PART OF ITS COMMITMENT TO ADDRESS GLOBAL INEQUITY IN LOW-INCOME COUNTRIES, AIM PARTNERED WITH PATIENT ADVOCACY IN AFRICA AND STARTED THE PROCESS OF PURSUING ACCESS PATHWAYS THAT WOULD ALLOW PATIENTS WITH MELANOMA, LIVING IN AFRICA, ACCESS TO TREATMENTS THEY NEEDED TO TREAT THEIR CANCER. IMWGIN APRIL 2006, AIM FORMED THE INTERNATIONAL MELANOMA WORKING GROUP (IMWG). THE IMWG IS BASED ON THE PREMISE THAT MELANOMA REQUIRES A FOCUSED, MULTI-DISCIPLINARY EFFORT AMONG THE WORLD'S LEADING MELANOMA INVESTIGATORS IN ORDER TO PROVIDE FOR A BETTER UNDERSTANDING OF THE BIOLOGY OF MELANOMA, TO ACCELERATE THE QUEST FOR MORE EFFECTIVE THERAPIES, AND EVENTUALLY TO DEVELOP A CURE FOR THE DISEASE. THE IMWG PROVIDES A THINK TANK ATMOSPHERE FOR THE WORLD'S LEADING MELANOMA EXPERTS TO GATHER AWAY FROM LARGE MEETINGS. SINCE ITS INCEPTION, IMWG HAS UNDERTAKEN SEVERAL KEY PROJECTS AS A RESULT OF COLLABORATION AMONG ITS MEMBERS AND CONTINUES TO WORK ON ADDITIONAL EFFORTS THAT WILL LEAD TO THE DEVELOPMENT OF MORE EFFECTIVE TREATMENT OPTIONS FOR MELANOMA PATIENTS. IMWG MEMBERS, WHICH CONSIST OF MELANOMA EXPERTS FROM THROUGHOUT THE WORLD, MET IN PERSON IN THE SPRING 2025 AND THE FALL OF 2025. AMONG ITS ACCOMPLISHMENTS IN 2025, THE IWMG CONTINUED TO WORK ON ITS INTERNATIONAL CLINICAL TRIAL NETWORK. AIM HAS OPENED AN INTERNATIONAL MELANOMA TISSUE BANK OF ANNOTATED FRESH FROZEN PRIMARY MELANOMA TISSUE AT OREGON HEALTH & SCIENCE UNIVERSITY'S KNIGHT CANCER INSTITUTE, CALIFORNIA PACIFIC MEDICAL CENTER, NORTHWESTERN UNIVERSITY'S ROBERT H. LURIE COMPREHENSIVE CANCER CENTER, UNIVERSITY OF PITTSBURGH CONTINUED LINE 4A FROM SCHEDULE OCANCER INSTITUTE; THE PETER MACCALLUM CANCER CENTER AND ALFRED HOSPITAL IN MELBOURNE ARE SIGNED ON TO PARTICIPATE BUT HAVE NOT BEGUN COLLECTING TISSUE. THE TISSUE BANK IS THE FUNDAMENTAL RESEARCH TOOL THAT DOES NOT EXIST YET FOR PUBLIC OR PRIVATE RESEARCH. MAJOR ADVANCES, PARTICULARLY WITHIN BREAST AND PROSTATE CANCER, RESULTED FROM SIMILAR BANKS. CONSEQUENTLY, MELANOMA RESEARCH LAGS SIGNIFICANTLY BEHIND THE PROGRESS THAT HAS BEEN MADE IN OTHER CANCER RESEARCH. IN 2025, THE BANK COLLECTED A TOTAL OF 24 TISSUES FROM U.S. SITES AND CONTINUED ITS EFFORT TO START COLLECTING TISSUE AT ITS AUSTRALIAN SITES. WIMIN AUGUST 2017, AIM FORMED WOMEN IN MELANOMA (WIM). WITH A GROWING NUMBER OF YOUNG WOMEN ONCOLOGISTS WITH AN INTEREST IN MELANOMA, AND AIM'S PROVEN TRACK RECORD FOR BRINGING TOGETHER MELANOMA EXPERTS, AIM FORMED WIM FOR THE PURPOSE OF SUPPORTING THE IMPROVEMENT OF MELANOMA PATIENT OUTCOMES THROUGH A FOCUS ON STRENGTHENING THE PHYSICIAN-PATIENT RELATIONSHIP, PROVIDING INSIGHTS INTO BEST PRACTICES IN COMMUNICATING WITH PATIENTS WITH MELANOMA TO IMPROVE OUTCOME, SUPPORTING THE ACADEMIC CAREERS OF YOUNG WOMEN WITH A RESEARCH INTEREST IN MELANOMA, AND FOSTERING MENTORING RELATIONSHIPS AMONG WOMEN ONCOLOGISTS WORKING IN THE FIELD OF MELANOMA. IN 2025, AIM HELD ITS NINTH ANNUAL MEETING IN LEESBURG, VA WHICH WAS ATTENDED BY UP-AND-COMING WOMEN ONCOLOGISTS, WITH A FOCUS ON MELANOMA. SINCE ITS INCEPTION, WIM MEMBERS HAVE SINCE UNDERTAKEN KEY RESEARCH PROJECTS AS A RESULT OF COLLABORATION AMONG ITS MEMBERS AT WIM MEETINGS. IN 2025 SAGE PUBLISHING AND THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY PUBLISHED PROCEEDINGS OF THE SEVENTH ANNUAL WOMEN IN MELANOMA CONFERENCE. THE ARTICLE EXTOLLED THE VIRTUES OF WIM TO A GLOBAL AUDIENCE.NURSE/PHYSICIAN EDUCATION INITIATIVEIN OCTOBER 2016, AIM CREATED THE MELANOMA NURSING INITIATIVE (MNI). THE RECENT EXPANSION OF MELANOMA THERAPY HAS INCREASED THE COMPLEXITY OF DISEASE MANAGEMENT. PATIENTS WITH MELANOMA MAY DISCONTINUE THERAPY IF NOT ADEQUATELY ENGAGED IN THEIR OWN CARE OR SUPPORTED WHEN THEY EXPERIENCE SIDE EFFECTS. AS WELL, MORE PATIENTS ARE BEING TREATED IN THE COMMUNITY SETTING, WHERE EXPERTISE IS FREQUENTLY LACKING TO ADDRESS THESE CHALLENGES. THE MNI CONSISTS OF:1. MELANOMA NURSE RESOURCE CENTER PORTAL (THEMELANOMANURSE.ORG)THIS PORTAL PROVIDES A 1-STOP SHOP FOR ALL THE EDUCATIONAL MATERIALS DEVELOPEDCONTENT INCLUDES CONSENSUS STATEMENTS, SIDE-EFFECT SEARCH FUNCTIONS, CME ACTIVITIES, A SUPPORTIVE CARE Q/A PORTAL, AND A PATIENT RESOURCE CENTER.2. MELANOMA NURSE MANAGEMENT TOOLKITHELPFUL RESOURCES SUCH AS ALGORITHMS, CHECKLISTS, PRINTABLE SHEETS, AND SEARCHABLE CONTENT ON SUPPORTIVE CARE ASPECTS OF MELANOMA THERAPY (SIDE EFFECT MANAGEMENT AS WELL AS ADHERENCE ISSUES), KEY RESOURCES ON TARGETED THERAPY, IMMUNOTHERAPY, AND INTRALESIONAL IMMUNOTHERAPY ONLINE RESOURCES AS WELL AS PRINT PIECES FOR DISTRIBUTION AT REGIONAL CANCER MEETING.3. DEVELOPMENT OF PATIENT RESOURCE MATERIALS CUSTOMIZED PATIENT RESOURCE/EDUCATION MATERIALS (PRINTABLE PDFS) HAVE BEEN DEVELOPED THAT CAN BE DOWNLOADABLE FROM THE WEBSITE AND DISTRIBUTED BY NURSES/PHYSICIAN ASSISTANTS AND OTHER HCPS. TOPICS INCLUDE THE GOALS OF THERAPY, THE SIDE EFFECTS OF THERAPIES, IMPORTANT POINTS/STRATEGIES AROUND ADHERENCE, AS WELL AS OTHER SUPPORTIVE RESOURCES, SUCH AS CALL-IN NUMBERS FOR FINANCIAL OR OTHER ASSISTANCE, ETC. SPECIFIC CONTENT ON TARGETED THERAPIES, IMMUNOTHERAPIES, COMBINATIONS, INTRALESIONAL IMMUNOTHERAPIES, AND THE ADJUVANT SETTING ARE INCLUDED.4. DEVELOPMENT OF PATIENT AND HCP VIDEOS HAVE BEEN DEVELOPED TO ADDRESS THE ISSUES OF PREVENTION AND EARLY DETECTION, SURGERY, PATHOLOGY, TREATMENT, SIDE EFFECTS AND MANAGMENET FOR BOTH TARGETED AND IMMUNOTHERAPIES, CLINICAL TRIALS, AND LIVING WITH MELANOMA. THE VIDEOS ARE AVAILABLE ON AIM AT MELANOMA SITE'S YOUTUBE CHANNEL.5. AIM PROVIDED WEB BASED EDUCATION ON STRATEGIES TO SUPPORT SHARED DECISION MAKING THE EDUCATION IS AVAILABLE AS WELL ON THE MNI WEBSITE. 1838518 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 14 0 1 9 1 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 1 1 0 0 0 CA X X THE ORGANIZATION 9167060599 3053 FREEPORT BLVD SUITE 222 SACRAMENTO CA 95818 JOHN KIRKWOOD DIRECTOR 3.00 X 0 0 0 MOHAMMED KASHANI-SABET DIRECTOR 3.00 X 0 0 0 RENU GUPTA DIRECTOR 1.00 X 0 0 0 HOWARD MAIBACH DIRECTOR 1.00 X 0 0 0 SAMANTHA GUILD PRESIDENT AND DIRECTOR 60.00 X X 214500 0 26593 ALICIA ROWELL VICE PRESIDENT 40.00 X 160508 0 0 375008 0 26593 2 0 1 0 0 802786 1786113 4533 2588899 CONSULTING 541900 9429 9429 HONORARIUM 541900 3475 3475 12904 229443 229443 4618 4533 85 85 85 10100 802786 169970 -159870 -159870 2671461 12904 0 69658 295000 295000 375008 348232 10725 16051 405819 345546 20891 39382 83617 74372 4819 4426 62281 55338 2522 4421 18023 18023 28097 28097 10764 10764 7114 7114 14741 14741 RESEARCH MEETINGS 228935 228935 PATIENT EDUCATION 211192 211192 GLOBAL ADVOCACY 99990 99990 PHYSICIAN/NURSE EDUCATI 75900 75900 141243 71249 18892 51102 2057724 1838518 103824 115382 772228 793770 5848509 6430540 36527 30098 10649 6429 35480 38138 6666866 7268877 19708 7982 19708 7982 X 0 0 0 0 6647158 7260895 6647158 7260895 6666866 7268877 613737 0 X X 0 1 X 1 0 X 2730026 2571483 3146314 2750295 2429029 13627147 2730026 2571483 3146314 2750295 2429029 13627147 6186310 7440837 13358 5328 86535 212479 229528 547228 157873 9500 12532 8315 12904 201124 14375499 0.51760 0.47910 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 36527 30098 6429 6429 PENSION PAYABLE 2500 CREDIT CARD PAYABLE 5482 7982 2588899 0 2588899 82562 82562 2671461 2057724 0 2057724 0 2057724 PART XI, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT INCOME 229,528. CONSULTING AND HONORARIUM 12,904. GROSS INCOME-FUNDRAISING EVENTS 10,100. DIRECT EXPENSES-FUNDRAISING EVENTS -169,970. STEPS AGAINST MELANOMA WALKS/RUNS 592244 592244 34977 3618 73077 IN MEMORY OF VAL GUILD 138693 130693 8000 30332 8244 1 81949 79849 2100 5852 7671 6199 812886 802786 10100 34977 36184 11289 87520 169970 -159870 1 MTBC MELANOMA TISSUE BANK CONSORTIUM 1779 MARKHAM WAY SACRAMENTO CA 95818 462454076 295000 0 TISSUE BANK X X 0 0 0 0 0 0 0 0 0 SAMANTHA GUILD PRESIDENT AND DIRECTOR 189500 0 25000 0 0 0 0 0 26593 0 241093 0 0 0 ALICIA ROWELL VICE PRESIDENT 160508 0 0 0 0 0 0 0 0 0 160508 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS SUBMITTED BY THE ACCOUNTANT TO THE GOVERNING BODY FOR REVIEW AND DISCUSSION. THE PRESIDENT APPROVES THE FILING OF FORM 990 BASED ON COMPLIANCE AND ACCURACY. THE ACCOUNTANT IS THEN GIVEN AUTHORIZATION TO FILE. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND APPLICABLE FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION WEBSITE AND TO THE PUBLIC UPON REQUEST. FORM 990 PART XII LINE 2C A COMMITTEE ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT, REVIEW OR COMPILATION OF ITS FINANCIAL STATEMENTS AND SELECTION OF ITS INDEPENDENT AUDITORS. THE ORGANIZATION DID NOT CHANGE ITS OVERSIGHT OR SELECTION PROCESS DURING THE TAX YEAR.